Details of the Drug

General Information of Drug (ID: DMJ1YQ2)

Drug Name

Epeleuton

Synonyms

Epeleuton; Epeleuton [INN]; 1667760-39-5; FA9BPX1T6V; (S,5Z,8Z,11Z,13E,17Z)-Ethyl 15-hydroxyicosa-5,8,11,13,17-pentaenoate; 5,8,11,13,17-Eicosapentaenoic acid, 15-hydroxy-, ethyl ester, (5Z,8Z,11Z,13E,15S,17Z)-; UNII-FA9BPX1T6V; 15(S)-HEPE-EE; CHEMBL5095178; AKOS040748327; 15(S)-HYDROXY-(5Z,8Z,11Z,13E,17Z)-EICOSAPENTAENOIC ACID ETHYL ESTER

Indication

Disease Entry	ICD 11	Status	REF
Hypertriglyceridemia	5C80.1	Phase 2	[1]
Non-alcoholic fatty liver disease	DB92	Phase 2	[2]
Sickle-cell disorder	3A51	Phase 2	[3]
Type 2 diabetes	5A11	Phase 2	[1]

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C22H34O3
Canonical SMILES: CCC=CCC(C=CC=CCC=CCC=CCCCC(=O)OCC)O
InChI: InChI=1S/C22H34O3/c1-3-5-15-18-21(23)19-16-13-11-9-7-6-8-10-12-14-17-20-22(24)25-4-2/h5-7,10-13,15-16,19,21,23H,3-4,8-9,14,17-18,20H2,1-2H3/b7-6-,12-10-,13-11-,15-5-,19-16+/t21-/m0/s1
InChIKey: DJYKWMOPVZGTRJ-PILRRHKESA-N

Cross-matching ID

PubChem CID: 133082733
UNII: FA9BPX1T6V
DrugBank ID: DB18100
TTD ID: DV8F9L

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT04365400) A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT02941549) A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered Epeleuton In NAFLD Patients. U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT05861453) An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease. U.S.National Institutes of Health.